GUIDED THERAPEUTIC Form 8-K February 14, 2013	S INC		
SECURITIES AND EXC	HANGE COMMIS	SSION	
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 1	.5(d) of the		
Securities Exchange Act of	f 1934		
Date of Report (Date of Ea	rliest Event) Februar	ry 14, 2013; (February 14, 2013)	
GUIDED THERAPEUT			
(Exact Name of Registran	t as Specified in Its (	Charter)	
Delaware	0-22179	58-2029543	

(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)

Incorporation)

5835 Peachtree Corners East, Suite D	30092
Norcross, Georgia	
(Address of Principal Executive Offices)	(Zip Code)
Registrant's Telephone Number, Includin	g Area Code: (770) 242-8723
Check the appropriate box below if the Fe the registrant under any of the following	orm 8-K filing is intended to simultaneously satisfy the filing obligation of provisions:
[] Written communications pursuant to	Rule 425 under the Securities Act (17 CFR 230.425)
[] Soliciting material pursuant to Rule 1	4a-12 under the Exchange Act (17 CFR 240.14a-12)
[] Pre-commencement communications	pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications	pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# **Section 7.01 (Regulation FD Disclosure)**

On February 14, 2013, the registrant publicly issued a press release announcing it had successfully passed its annual ISO quality audit necessary for continued CE Mark certification as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

### **Number** Exhibit

99.1 Press Release dated February 14, 2013.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## **GUIDED THERAPEUTICS, INC.**

By: <u>/s/ Mark L. Faupel, Ph.D.</u>
Mark L. Faupel, Ph.D.
CEO & President

Date: February 14, 2012

2